Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push
Dice is a biopharmaceutical company that uses a proprietary technology platform to develop new oral therapeutic drugs for autoimmune diseases.
Source link
- Hyperline is a billing platform for SaaS products
- The counterfeit lawsuits that scoop up hundreds of Chinese Amazon sellers at once
